Virax Biolabs Group Limited
VRAX · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -96% | 1,727.1% | – | – |
| Gross Profit | -$0 | $0 | -$0 | $0 |
| % Margin | -838.2% | 32.3% | -15.9% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -91,649.5% | -4,225.3% | -63,570.7% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -95,739.2% | -4,304.8% | -63,748.3% | – |
| EPS Diluted | -1.95 | -3.36 | -5.13 | -1.5 |
| % Growth | 42% | 34.5% | -242% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |